Australia/USA-based Spinifex Pharmaceuticals, a pain drug development company, has announced the appointment of Ronald Marcus as Chief Medical Officer. Dr Marcus will be responsible for driving the development of Spinifex’s lead candidate EMA401 and the company’s pre-clinical pipeline.
Dr Marcus has more than 20 years’ pharmaceutical clinical development experience. He joins Spinifex following a career at Bristol-Myers Squibb (BMS), having held a number of senior leadership positions within BMS’s Neuroscience division.
Dr Marcus received a BA in Psychology from University of Virginia. He earned his medical degree from SUNY Buffalo and completed his Psychiatry residency and NIMH research fellowship at Cornell University, New York Hospital-Westchester Division. He has authored more than 80 peer-reviewed publications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze